Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7933576 | 0.93 | ALDH1A1 (0.39) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3309868 | 0.88 | DNM1 (0.46) | LMNATSHRDNM1CA12CA1 | |
| SCHEMBL23736384 | 0.86 | MEN1 (0.35) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL9395742 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL3365357 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL611689 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL9396454 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL10379464 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL9815759 | 0.85 | DNM1 (0.50) | TSHRDNM1CA12CA1CA2 | |
| SCHEMBL865718 | 0.85 | DNM1 (0.43) | TSHRDNM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021236449-A1 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096903-A1 | SULFAMOYL-CONTAINING DERIVATIVES AND USES THEREOF | HSP90AB2P, HSP90AB1, HSP90AA1 | SMN1; SMN2 2656/4885LMNA 4433/4885ALDH1A1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.